SEC Tracker
Get the app

Oncocyte IMDX

Oncocyte FY 2022: revenue $958K, down 88%; diluted EPS −$13.25

Form
10-K/A
Filed
Period
Importance
Routine
Document
10-K/A

Key figures from this report

These are the numbers Oncocyte reported for the year ended Dec 31, 2022, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$958K−88% from $7.7M in FY 202110-K income statement, on EDGAR
  2. Net income−$72.9MAgainst −$64.1M in FY 202110-K income statement, on EDGAR
  3. Diluted EPS−$13.25No year-earlier figure tagged10-K income statement, on EDGAR
  4. Cash and cash equivalents$20.0M−44% from $35.6M in FY 202110-K balance sheet, on EDGAR
  5. Cash from operations−$45.6MAgainst −$35.9M in FY 202110-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Oncocyte files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2835 and related industry codes: the same peer list as the financial tables.

  1. Rein Therapeutics RNTX public float $32M, Jun 30, 2025
  2. Yarrow Bioscience VYNE public float $32M, Jun 30, 2025
  3. Kezar Life Sciences KZR public float $33M, Jun 30, 2025
  4. Scorpius Holdings SCPX
  5. Provectus Biopharmaceuticals PVCT public float $31M, Jun 30, 2025